logo
  Join        Login             Stock Quote

Navidea's (NAVB) Imaging Drug For Lymph Node Mapping Wins FDA Nod

 March 13, 2013 11:45 AM


(By Balachander) Navidea Biopharmaceuticals Inc.'s (NYSEAMEX: NAVB) imaging drug - Lymphoseek injection - for lymph node mapping has been approved by the U.S. health regulators.

Lymphoseek, a radioactive diagnostic imaging agent, helps doctors locate lymph nodes in patients with breast cancer or melanoma.

The U.S. Food and Drug Administration (FDA) said Lymphoseek is the first new drug used for lymph node mapping to be approved in more than 30 years.

"To use Lymphoseek, doctors inject the drug into the tumor area and later, using a handheld radiation detector, find lymph nodes that have taken up Lymphoseek's radioactivity," the FDA said.

InĀ  two clinical trialsĀ  patients were injected with Lymphoseek and blue dye, another drug used to help locate lymph nodes. Results showed Lymphoseek and blue dye had localized most lymph nodes, although a notable number of nodes were localized only by Lymphoseek, the FDA said.

The FDA noted that most common side effects identified in clinical trials was pain or irritation at the injection site.

Dublin, Ohio-based Navidea's Lymphoseek is designed to identify the lymph nodes that drain from a primary tumor, which have the highest probability of harboring cancer.

According to the American Cancer Society, approximately 229,000 new cases of breast cancer and 76,000 new cases of melanoma are expected to be diagnosed in the United States in 2012.

The stock, which has been trading in the 52-week range of $2.14 to $4.77, retreated 5.57 percent to trade at $3.22 at 11.42 am ET on Wednesday.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageGermany Is On The Rebound - Time To Buy?

Based on this year's 17% spike in the Stoxx Europe 600 Index, it seems investors have found a home in read on...

article imageIs Drought Risk In The American West An Economic Threat?

The historic and ongoing drought in California is getting harder to ignore in terms of its potential impact read on...

article imageFunds Behaving Badly

Discipline is still the key to read on...

article imageGenuine Parts Co. (GPC): This Company's Raised Dividends For 59 Years

There are 253 million cars and trucks driving along U.S. roads. And the average age of those automobiles is read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center

Related Articles:

Recent Articles by Balachander
More Articles on: Medical



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.